Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model

[1]  S. Lilienfeld.  Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. , 2006, CNS drug reviews.

[2]  D. Braida,et al.  Eptastigmine: ten years of pharmacology, toxicology, pharmacokinetic, and clinical studies. , 2006, CNS drug reviews.

[3]  P. Deyn,et al.  Analysis of cholinergic markers, biogenic amines, and amino acids in the CNS of two APP overexpression mouse models , 2005, Neurochemistry International.

[4]  M. Staufenbiel,et al.  APP23 Mice as a Model of Alzheimer's Disease: An Example of a Transgenic Approach to Modeling a CNS Disorder , 2005, CNS Spectrums.

[5]  Derek A. Hamilton,et al.  Rodent spatial navigation: at the crossroads of cognition and movement , 2004, Neuroscience & Biobehavioral Reviews.

[6]  S. Engelborghs,et al.  Altered circadian locomotor activity in APP23 mice: a model for BPSD disturbances , 2004, The European journal of neuroscience.

[7]  J. Krueger,et al.  Differences in spatial learning comparing transgenic p75 knockout, New Zealand Black, C57BL/6, and Swiss Webster mice , 2004, Behavioural Brain Research.

[8]  Pierre N Tariot,et al.  Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. , 2004, JAMA.

[9]  K. Komatsu,et al.  Repair of amyloid β(25–35)-induced memory impairment and synaptic loss by a Kampo formula, Zokumei-to , 2003, Brain Research.

[10]  S. Wonnacott,et al.  The allosteric potentiation of nicotinic acetylcholine receptors by galantamine is transduced into cellular responses in neurons: Ca2+ signals and neurotransmitter release. , 2003, Molecular pharmacology.

[11]  O. Cauli,et al.  Memantine presents different effects from MK-801 in motivational and physical signs of morphine withdrawal , 2003, Behavioural Brain Research.

[12]  J. Kornhuber,et al.  Memantine in moderate-to-severe Alzheimer's disease. , 2003, The New England journal of medicine.

[13]  Martin Radina,et al.  Galantamine Is an Allosterically Potentiating Ligand of Neuronal Nicotinic but Not of Muscarinic Acetylcholine Receptors , 2003, Journal of Pharmacology and Experimental Therapeutics.

[14]  E. Baldi,et al.  Task solving by procedural strategies in the Morris water maze , 2003, Physiology & Behavior.

[15]  P. Kelly,et al.  Progressive age-related impairment of cognitive behavior in APP23 transgenic mice , 2003, Neurobiology of Aging.

[16]  R. D'Hooge,et al.  Age‐dependent cognitive decline in the APP23 model precedes amyloid deposition , 2003, The European journal of neuroscience.

[17]  J. Miguel-Hidalgo,et al.  Neuroprotection by memantine against neurodegeneration induced by β-amyloid(1–40) , 2002, Brain Research.

[18]  M. Staufenbiel,et al.  Spatial learning, exploration, anxiety, and motor coordination in female APP23 transgenic mice with the Swedish mutation , 2002, Brain Research.

[19]  M. S. Levi,et al.  A review of chemical agents in the pharmacotherapy of addiction. , 2002, Current medicinal chemistry.

[20]  R. Bullock,et al.  A MULTINATIONAL, RANDOMISED, 12‐WEEK, COMPARATIVE STUDY OF DONEPEZIL AND RIVASTIGMINE IN PATIENTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE , 2002, International journal of clinical practice.

[21]  Yasuo Arai,et al.  Research and development of donepezil hydrochloride, a new type of acetylcholinesterase inhibitor. , 2002, Japanese journal of pharmacology.

[22]  P. Kelly,et al.  Cholinergic Changes in the APP23 Transgenic Mouse Model of Cerebral Amyloidosis , 2002, The Journal of Neuroscience.

[23]  E. Wei,et al.  Reversal of scopolamine-induced spatial memory deficits in rats by TAK-147. , 2002, Acta pharmacologica Sinica.

[24]  George A. Carlson,et al.  The Relationship between Aβ and Memory in the Tg2576 Mouse Model of Alzheimer's Disease , 2002, The Journal of Neuroscience.

[25]  R. Dempsey,et al.  Neuroprotection by memantine, a non-competitive NMDA receptor antagonist after traumatic brain injury in rats , 2001, Brain Research.

[26]  R. D'Hooge,et al.  Applications of the Morris water maze in the study of learning and memory , 2001, Brain Research Reviews.

[27]  D. Selkoe.  Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.

[28]  G. Wilcock,et al.  Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial , 2000, BMJ : British Medical Journal.

[29]  M. Staufenbiel,et al.  Pathogenic Mechanisms of Alzheimer's Disease Analyzed in the APP23 Transgenic Mouse Model , 2000, Annals of the New York Academy of Sciences.

[30]  L. Wilkins.  Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension , 2000, Neurology.

[31]  A. Maelicke.  Allosteric Modulation of Nicotinic Receptors as a Treatment Strategy for Alzheimer’s Disease , 2000, Dementia and Geriatric Cognitive Disorders.

[32]  P. Tariot,et al.  A 5-month, randomized, placebo-controlled trial of galantamine in AD , 2000, Neurology.

[33]  R. Bartus,et al.  On Neurodegenerative Diseases, Models, and Treatment Strategies: Lessons Learned and Lessons Forgotten a Generation Following the Cholinergic Hypothesis , 2000, Experimental Neurology.

[34]  R. Doody,et al.  Long-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: final analysis of a US multicentre open-label study , 2000, European Neuropsychopharmacology.

[35]  R. D'Hooge,et al.  Animal models of human disorders - General aspects , 2000 .

[36]  H. Ogura,et al.  Donepezil, a centrally acting acetylcholinesterase inhibitor, alleviates learning deficits in hypocholinergic models in rats. , 2000, Methods and findings in experimental and clinical pharmacology.

[37]  G. Koob.  Neurobiology of Addiction: Toward the Development of New Therapies , 2000, Annals of the New York Academy of Sciences.

[38]  R. D'Hooge,et al.  Age‐related behavioural deficits in transgenic mice expressing the HIV‐1 coat protein gp120 , 1999, The European journal of neuroscience.

[39]  M. Weinstock,et al.  Effect of rivastigmine on scopolamine-induced memory impairment in rats. , 1999, European journal of pharmacology.

[40]  T. Ballard,et al.  The acetylcholinesterase inhibitor, ENA 713 (Exelon), attenuates the working memory impairment induced by scopolamine in an operant DNMTP task in rats , 1999, Psychopharmacology.

[41]  C. Parsons,et al.  Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist—a review of preclinical data , 1999, Neuropharmacology.

[42]  H. Möller.  Reappraising neurotransmitter-based strategies , 1999, European Neuropsychopharmacology.

[43]  Y. Agid,et al.  Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trialCommentary: Another piece of the Alzheimer's jigsaw , 1999 .

[44]  A. Doble.  The role of excitotoxicity in neurodegenerative disease: implications for therapy. , 1999 .

[45]  B. Winblad,et al.  Memantine in severe dementia: results of the 9M‐best study (benefit and efficacy in severly demented patients during treatment with memantine) , 1999, International journal of geriatric psychiatry.

[46]  R. Strong,et al.  Neurochemical changes in the aging human brain: implications for behavioral impairment and neurodegenerative disease. , 1998, Geriatrics.

[47]  W. Danysz,et al.  ETHANOL‐REINFORCED BEHAVIOUR IN THE RAT: EFFECTS OF THE UNCOMPETITIVE NMDA RECEPTOR ANTAGONIST, MEMANTINE , 1998, European journal of pharmacology.

[48]  X. Tang,et al.  Reversal of scopolamine-induced deficits in radial maze performance by (-)-huperzine A: comparison with E2020 and tacrine. , 1998, European journal of pharmacology.

[49]  Ken-ichi Tanaka,et al.  Ameliorating Effects of SDZ ENA 713 on Age-Associated Decreases in Learning Performance and Brain Choline Acetyltransferase Activity in Rats , 1997, Brain Research Bulletin.

[50]  D. Cain,et al.  Fractionating the nonspatial pretraining effect in the water maze task. , 1997, Behavioral neuroscience.

[51]  B. Sommer,et al.  Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[52]  M. D. Lindner.  Reliability, Distribution, and Validity of Age-Related Cognitive Deficits in the Morris Water Maze , 1997, Neurobiology of Learning and Memory.

[53]  E. Levin,et al.  Nicotinic System Involvement in Alzheimer’s and Parkinson’s Diseases , 1997, Drugs & aging.

[54]  E X Albuquerque,et al.  Properties of neuronal nicotinic acetylcholine receptors: pharmacological characterization and modulation of synaptic function. , 1997, The Journal of pharmacology and experimental therapeutics.

[55]  D. Cain,et al.  Testing hypotheses of spatial learning: the role of NMDA receptors and NMDA-mediated long-term potentiation , 1997, Behavioural Brain Research.

[56]  P. Popik,et al.  Inhibition of reinforcing effects of morphine and motivational aspects of naloxone-precipitated opioid withdrawal by N-methyl-D-aspartate receptor antagonist, memantine. , 1997, The Journal of pharmacology and experimental therapeutics.

[57]  N. Demura,et al.  SDZ ENA 713 facilitates central cholinergic function and ameliorates spatial memory impairment in rats , 1997, Behavioural Brain Research.

[58]  R. D'Hooge,et al.  Spatial learning deficit in mice expressing human 751-amino acid beta-amyloid precursor protein. , 1996, Neuroreport.

[59]  H. Hodges.  Maze procedures: the radial-arm and water maze compared. , 1996, Brain research. Cognitive brain research.

[60]  C. Barnes,et al.  The neurochemical and behavioral effects of β-amyloid peptide(25–35) , 1996, Brain Research.

[61]  D. Braida,et al.  An inverted U-shaped curve for heptylphysostigmine on radial maze performance in rats: comparison with other cholinesterase inhibitors. , 1996, European journal of pharmacology.

[62]  J. Winslow,et al.  α2-Adrenoceptor antagonists potentiate acetylcholinesterase inhibitor effects on passive avoidance learning in the rat , 1996, Psychopharmacology.

[63]  C. Barnes,et al.  Effects of the Uncompetitive NMDA Receptor Antagonist Memantine on Hippocampal Long‐term Potentiation, Short‐term Exploratory Modulation and Spatial Memory in Awake, Freely Moving Rats , 1996, The European journal of neuroscience.

[64]  J. Hall,et al.  Detailed behavioral analysis of water maze acquisition under APV or CNQX: contribution of sensorimotor disturbances to drug-induced acquisition deficits. , 1996, Behavioral neuroscience.

[65]  C. Parsons,et al.  Learning deficits induced by chronic intraventricular infusion of quinolinic acid--protection by MK-801 and memantine. , 1996, European journal of pharmacology.

[66]  S. L. Mobley,et al.  MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis. , 1995, European journal of pharmacology.

[67]  Takashi Yamaguchi,et al.  Effect of YM796, a novel muscarinic agonist, on the impairment of passive avoidance response in senescence-accelerated mice , 1995, Pharmacology Biochemistry and Behavior.

[68]  M. Takeda,et al.  Effects of SDZ ENA 713, novel acetyl cholinesterase inhibitor, on learning of rats with basal forebrain lesions , 1995, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[69]  J. Waite,et al.  The behavioral effects of heptylphysostigmine on rats lesioned in the nucleus basalis , 1995, Neuroscience Research.

[70]  H. Yamashita,et al.  Characterization of a novel muscarinic receptor agonist, YM796: comparison with cholinesterase inhibitors in in vivo pharmacological studies. , 1994, European journal of pharmacology.

[71]  G. Dawson,et al.  The effects of novel cholinesterase inhibitors and selective muscarinic receptor agonists in tests of reference and working memory , 1993, Behavioural Brain Research.

[72]  S. Yoshida,et al.  Antiamnesic and cholinomimetic side-effects of the cholinesterase inhibitors, physostigmine, tacrine and NIK-247 in rats. , 1993, European journal of pharmacology.

[73]  W. Carlezon,et al.  D-cycloserine attenuates scopolamine-induced learning and memory deficits in rats. , 1993, Behavioral and neural biology.

[74]  R. Görtelmeyer,et al.  Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study. , 1992, Arzneimittel-Forschung.

[75]  K. Ditzler.  Efficacy and tolerability of memantine in patients with dementia syndrome. A double-blind, placebo controlled trial. , 1991, Arzneimittel-Forschung.

[76]  A. Ueki,et al.  Reversal of learning impairment in ventral globus pallidus-lesioned rats by combination of continuous intracerebroventricualr choline infusion and oral cholinergic drug administration , 1991, Brain Research.

[77]  E. Mohr,et al.  Neurochemical substrates of human aging and dementia. , 1990, Pharmacopsychiatry.

[78]  P. Davies,et al.  Recent advances in the neurochemistry of Alzheimer's disease. , 1987, The Journal of clinical psychiatry.

[79]  Robert S. Pinals,et al.  A double‐blind, placebo‐controlled trial , 1986 .

[80]  D L Price,et al.  Alzheimer's disease: a disorder of cortical cholinergic innervation. , 1983, Science.

[81]  M. Jarvik,et al.  Cholinergic receptor interactions and their effects on long-term memory processing , 1981, Brain Research.

[82]  P. Davies,et al.  SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE , 1976, The Lancet.

[83]  J. Coyle,et al.  Effects of different doses of galanthamine, a long-acting acetylcholinesterase inhibitor, on memory in mice , 2005, Psychopharmacology.

[84]  Luc Truyen,et al.  A Long-Term Comparison of Galantamine and Donepezil in the Treatment of Alzheimer’s Disease , 2003, Drugs & aging.

[85]  S. Younkin,et al.  The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. , 2002, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[86]  J. Miguel-Hidalgo,et al.  Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40). , 2002, Brain research.

[87]  Y. Agid,et al.  Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. , 1999, BMJ.

[88]  E X Albuquerque,et al.  Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. , 1996, Molecular pharmacology.

[89]  C. Barnes,et al.  The neurochemical and behavioral effects of beta-amyloid peptide(25-35). , 1996, Brain research.

[90]  M. Chorev,et al.  Pharmacological evaluation of phenyl-carbamates as CNS-selective acetylcholinesterase inhibitors. , 1994, Journal of neural transmission. Supplementum.

[91]  T. Thomsen,et al.  Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo. , 1990, Life sciences.